GSK in talks to buy cancer biotech Nuvalent for more than $9bn

GSK is currently engaged in negotiations to acquire the cancer biotech company Nuvalent for a price exceeding $9 billion. This potential transaction would represent one of the largest acquisitions for the UK drugmaker. The deal comes during a period of increased M&A activity within the biotech sector this year. Reports indicate that the pharmaceutical giant is seeking to expand its oncology portfolio through this significant investment in the specialized cancer drugmaker Nuvalent.